


Neoadjuvant *in situ* vaccination with cowpea mosaic virus as a novel therapy against canine inflammatory mammary cancer.



Authors

Daniel Alonso-Miguel, Guillermo Valdivia, Diego Guerrero, Maria Dolores Perez-Alenza, Stanislav Pantelyushin, Angela Alonso-Diez, Veronique Beiss, Steven Fiering, Nicole F. Steinmetz, Maria Suárez, Johannes vom Berg, Laura Peña, Hugo Arias-Pulido.

Correspondence

hugo.ariaspulido@dartmouth.edu

In brief

Two neoadjuvant intratumoral (*in situ*) eCPMV injections led to tumor shrinkage, increased survival, and good quality of life with no adverse events. eCPMV-injected tumors have a strong neutrophilic-mediated cell death, increased CD3⁺ T lymphocyte infiltration, and decreased in FoxP3⁺ T cells, while a significant decrease in Treg/CD8⁺ ratio was observed in peripheral blood.